An interventional study of SUPRA SDRM in Chronic Wound, Leg Ulcer and Venous Leg Ulcer, sponsored by Polymedics Innovations Inc.. Completed at 1 site in Austria. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by Polymedics Innovations Inc. · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this clinical trial is to learn how SUPRA SDRM affects the healing of chronic wounds. SUPRA SDRM is a synthetic wound covering that slowly breaks down on the wound. The trial includes adults aged 18 to 80 with a leg or foot wound that has not healed for at least 3 months. As a small pilot trial, it helps plan larger trials.
The main questions it aims to answer are:
All participants receive SUPRA SDRM. There is no comparison group.
Participants:
Rationale SUPRA SDRM is a fully synthetic, biodegradable wound matrix made of a lactide-based terpolymer. It is CE-marked for chronic wounds and is used within its intended purpose. As no clinical studies of SUPRA SDRM were available at the time of planning, this pilot study is descriptive and is intended to generate data for sample size calculation of future comparative studies.
Procedures After a 2-week run-in with standard of care to confirm wound size stability, SUPRA SDRM is applied and changed weekly for up to 12 weeks. Before each application, the wound is cleansed and, if indicated, non-surgically debrided. SUPRA SDRM is covered with a wound contact layer and a secondary dressing. If the wound heals before week 12, application stops while assessments continue.
Measurement methods Wound area is determined from standardized photographs using image analysis software. Perfusion is assessed by laser Doppler imaging, hyperspectral imaging and thermal imaging. Wound swabs and pH measurements are taken before wound cleansing. Wound exudate and removed matrices are analyzed for wound healing-related biomarkers in an external laboratory.
Statistical analysis Analysis is descriptive without hypothesis testing. Data are reported as mean and standard deviation or median and quartiles with 95% confidence intervals per time point, following the intention-to-treat principle.
1,079 studies on the registry are indexed under Diabetic Foot; 222 are open to participants now.
This study's enrollment of 10 is below the median of 60 across 849 interventional studies indexed under Diabetic Foot.
Browse Diabetic Foot studies →Polymedics Innovations Inc. is the lead sponsor of 2 studies on the registry; none are open to participants now.
Compared within Diabetic Foot, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Leg Ulcer. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive SUPRA SDRM on their chronic wound after a 2-week run-in period with standard of care. SUPRA SDRM is changed once weekly for up to 12 weeks, followed by follow-up visits after 4 and 6 months.
Device: SUPRA SDRM
CE-marked, fully synthetic, biodegradable wound matrix made of a lactide-based terpolymer. Applied to the cleansed wound, covered with a wound contact layer and a secondary dressing, and changed once weekly for up to 12 weeks.
Also known as: SUPRA SDRM CW
Remaining Wound Area
Percentage of remaining wound area relative to baseline, determined from standardized wound photographs using image analysis software (e.g. ImageJ).
Time frame: Baseline and weekly (every 7 ± 2 days) up to week 12
Wound Characteristics Assessed by the Hollander Wound Evaluation Scale (HWES)
Investigator-assessed wound characteristics using the HWES (6 dichotomous items; total score 0-6, higher scores indicate a worse outcome).
Time frame: Baseline and weekly (every 7 ± 2 days) up to week 12
Wound Characteristics Assessed by the HWES at Follow-up
Investigator-assessed wound characteristics using the Hollander Wound Evaluation Scale (6 dichotomous items; total score 0-6, higher scores indicate a worse outcome).
Time frame: 4 and 6 months
Wound Blood Flow Assessed by Laser Doppler Imaging
Microcirculatory blood flow in the wound area (region of interest), measured in perfusion units (flux).
Time frame: Baseline, weekly (every 7 ± 2 days) up to week 12, and at 4 and 6 months
Wound Temperature Assessed by Thermal Imaging
Skin temperature in the wound area (region of interest), measured in °C.
Time frame: Baseline, weekly (every 7 ± 2 days) up to week 12, and at 4 and 6 months
Wound Tissue Oxygenation Assessed by Hyperspectral Imaging
Tissue oxygen saturation in the wound area (region of interest), measured in %.
Time frame: Baseline, weekly (every 7 ± 2 days) up to week 12, and at 4 and 6 months
Number of Participants With Bacterial Colonization of the Wound
Number of participants with a positive microbiological wound swab culture, determined by microbiological wound swabs and culture. Identified species are reported descriptively.
Time frame: Baseline, weekly (every 7 ± 2 days) up to week 12, and at 4 and 6 months
Wound pH
Wound surface pH measured with a pH meter (range 0-14).
Time frame: Baseline, weekly (every 7 ± 2 days) up to week 12, and at 4 and 6 months
Health-Related Quality of Life Assessed by the Wound-QoL Questionnaire
Wound-specific health-related quality of life using the Wound-QoL (17 items, each scored 0-4; total score 0-68, lower scores indicate better quality of life).
Time frame: Baseline, week 12, and at 4 and 6 months
Systemic Inflammation Markers I (Leucocytes)
Title: Leukocyte Count Description: Leukocyte count in routine laboratory blood tests, measured in 10\^9/L.
Time frame: Screening, every 4 weeks during the 12-week treatment period, and at 4 and 6 months
Systemic Inflammation Markers II (CRP)
Title: Serum C-Reactive Protein (CRP) Concentration Description: CRP concentration in routine laboratory blood tests, measured in mg/L.
Time frame: Screening, every 4 weeks during the 12-week treatment period, and at 4 and 6 months
Wound Healing-Related Biomarkers in Wound Exudate (Protein)
Title: Total Protein Concentration in Wound Exudate Description: Total protein concentration in wound exudate, determined by BCA assay, measured in mg/mL.
Time frame: Baseline, weekly (every 7 ± 2 days) up to week 12, and at 4 and 6 months
Wound Healing-Related Biomarkers in Wound Exudate (MMP)
Title: Matrix Metalloproteinase (MMP) Activity in Wound Exudate Description: MMP activity in wound exudate, determined by fluorogenic substrate assay and expressed as MMP-9-equivalent concentration in nM.
Time frame: Baseline, weekly (every 7 ± 2 days) up to week 12, and at 4 and 6 months
Wound Healing-Related Biomarkers in Wound Exudate (Elastase)
Title: Elastase Activity in Wound Exudate Description: Human neutrophil elastase activity in wound exudate, determined by fluorogenic substrate assay and expressed as elastase-equivalent concentration in nM.
Time frame: Baseline, weekly (every 7 ± 2 days) up to week 12, and at 4 and 6 months
Wound Healing-Related Biomarkers in Wound Exudate II (MPO)
Title: Myeloperoxidase (MPO) Activity in Wound Exudate Description: MPO activity in wound exudate, determined by colorimetric assay, measured in mU/mL.
Time frame: Baseline, weekly (every 7 ± 2 days) up to week 12, and at 4 and 6 months
Wound Healing-Related Biomarkers in Wound Exudate (Chemokine: MCP-1)
Title: Monocyte Chemoattractant Protein-1 (MCP-1) Concentration in Wound Exudate Description: MCP-1 concentration in wound exudate swabs, measured in pg/mL.
Time frame: Baseline, weekly (every 7 ± 2 days) up to week 12, and at 4 and 6 months
Wound Healing-Related Biomarkers in Wound Exudate I (Cytokine: IL-1β)
Title: Interleukin-1β (IL-1β) Concentration in Wound Exudate Description: IL-1β concentration in wound exudate swabs, measured in pg/mL.
Time frame: Baseline, weekly (every 7 ± 2 days) up to week 12, and at 4 and 6 months
Wound Healing-Related Biomarkers in Wound Exudate II (Cytokine: IL-6)
Title: Interleukin-6 (IL-6) Concentration in Wound Exudate Description: IL-6 concentration in wound exudate swabs, measured in pg/mL.
Time frame: Baseline, weekly (every 7 ± 2 days) up to week 12, and at 4 and 6 months
Wound Healing-Related Biomarkers in Wound Exudate III (Cytokine: TNF-α)
Title: Tumor Necrosis Factor-α (TNF-α) Concentration in Wound Exudate Description: TNF-α concentration in wound exudate swabs, measured in pg/mL.
Time frame: Baseline, weekly (every 7 ± 2 days) up to week 12, and at 4 and 6 months
Remaining Wound Area at Follow-up
Percentage of remaining wound area relative to baseline, determined from standardized wound photographs using image analysis software (e.g. ImageJ).
Time frame: 4 and 6 months
Plan to share: No — Individual participant data will not be shared due to the small sample size and the associated risk of re-identification, and because data sharing with third parties was not covered by participant consent.
No publications or documents are linked to this record.
Ran from Aug 2023 to primary completion in Feb 2025, 18 months.
Of 104 industry-sponsored interventional studies with no phase under Diabetic Foot, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 40. This study's 18 months is below that.
Counting every sponsor, half of 344 studies reached it within 22 months; a quarter within 9 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Polymedics Innovations Inc.